Cryptococcus infection medical therapy

Jump to navigation Jump to search

Cryptococcus infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cryptococcus infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cryptococcus infection medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cryptococcus infection medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cryptococcus infection medical therapy

CDC on Cryptococcus infection medical therapy

Cryptococcus infection medical therapy in the news

Blogs on Cryptococcus infection medical therapy

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Cryptococcus infection medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Medical Therapy

Antimicrobial Regimen

  • Cryptococcus Meningoencephalitis in Human Immunodeficiency Virus–Infected Individuals
    • Induction Therapy
  • Preferred regimen (1): Amphotericin B deoxycholate (0.7–1.0 mg/kg per day) plus flucytosine (100 mg/kg per day) for 2 weeks Template:AND Begin HAART 2–10 weeks after the start of initial antifungal treatment.
  • Preferred regimen (2): Liposomal AmB (3–4 mg/kg per day) or ABLC (5 mg/kg per day, with renal function concerns) plus flucytosine (100 mg/kg per day) for 2 weeks Template:AND Begin HAART 2–10 weeks after the start of initial antifungal treatment.
  • Preferred regimen (3): AmBd (0.7–1.0 mg/kg per day) or liposomal AmB (3–4 mg/kg per day) or ABLC (5 mg/kg per day, for flucytosine-intolerant patients)

References